KHKathryn V. Holmes

Kathryn V. Holmes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kathryn V. Holmes has a total of 103 co-authors. Here are the top co-authors by number of shared publications:

  • Bruce D. Zelus

    Department of Microbiology,1 Molecular Biology Program, University of Colorado Health Sciences Center, Denver, Colorado 80262,3 INRS-Institut Armand-Frappier, Laval, Québec, Canada H7V 1B72

    4 shared publications
  • Erin M. Hemmila

    University of Colorado Health Sciences Center at Fitzsimons

    4 shared publications
  • Larissa B. Thackray

    Department of Microbiology,1 Graduate Program in Molecular Biology, University of Colorado Denver School of Medicine, Aurora, Colorado 800452

    4 shared publications
  • David E. Wentworth

    Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA

    3 shared publications
  • Emily A. Travanty

    Department of Microbiology,1 Graduate Program in Molecular Biology, University of Colorado Denver School of Medicine, Aurora, Colorado 800452

    3 shared publications
  • M. K. Smith

    Department of Microbiology,1 Graduate Program in Molecular Biology, University of Colorado Denver School of Medicine, Aurora, Colorado 800452

    3 shared publications

Latest Publications

  • Open Access

    Peptide Nanocapsules As Novel Immunogens:Design And Biophysical Analysis Of A Prototype SARS Vaccine

    by Tais Pimentel, Zhe Yan, Scott A. Jeffers, Kathryn V. Holmes, Robert S. Hodges, Peter Burkhard

  • Bats Prove To Be Rich Reservoirs for Emerging Viruses

    by Charles H. Calisher, Kathryn V. Holmes, Tony Schountz, Samuel R. Dominguez, Paul Cryan

    Emerging pathogens, many of them viruses, continue to surprise us, providing many newly recognized diseases to study and to try to control. Many of these emergent viruses are zoonotic, transmitted from reservoirs in wild or domestic animals to humans, either by insect vectors or by exposure to the droppings or tissues of such animals. One rich— but, until recently, underappreciated—source of emergent viruses is bats (Chiroptera, meaning “hand wing”). Accounting for 1,116, or nearly one-fourth, of the 4,600 recognized species of mammals, bats are grouped into two suborders — Megachiroptera, which contains a single family, Pteropodidae, consisting of 42 genera and 186 species, and Microchiroptera, which contains 17 families, 160 genera, and 930 species.


  • Open Access

    Prior Evidence of Putative Novel Rhinovirus Species, Australia

    by Thomas Briese, Gustavo Palacios, W. Ian Lipkin, Neil Renwick, Marietjie Venter, Richard G. Jarman, Samuel R. Dominguez, Kathryn V. Holmes, Edward C. Holmes

  • Aromatic Amino Acids in the Juxtamembrane Domain of Severe Acute Respiratory Syndrome Coronavirus Spike Glycoprotein Are Important for Receptor-Dependent Virus Entry and Cell-Cell Fusion

    by Megan W. Howard, Emily A. Travanty, Scott A. Jeffers, M. K. Smith, Sonia T. Wennier, Larissa B. Thackray, Kathryn V. Holmes

    The severe acute respiratory syndrome coronavirus (SARS-CoV) spike glycoprotein (S) is a class I viral fusion protein that binds to its receptor glycoprotein, human angiotensin converting enzyme 2 (hACE2), and mediates virus entry and cell-cell fusion. The juxtamembrane domain (JMD) of S is an aromatic amino acid-rich region proximal to the transmembrane domain that is highly conserved in all coronaviruses. Alanine substitutions for one or two of the six aromatic residues in the JMD did not alter the surface expression of the SARS-CoV S proteins with a deletion of the C-terminal 19 amino acids (S Δ19) or reduce binding to soluble human ACE2 (hACE2). However, hACE2-dependent entry of trypsin-treated retrovirus pseudotyped viruses expressing JMD mutant S Δ19 proteins was greatly reduced. Single alanine substitutions for aromatic residues reduced entry to 10 to 60% of the wild-type level. The greatest reduction was caused by residues nearest the transmembrane domain. Four double alanine substitutions reduced entry to 5 to 10% of the wild-type level. Rapid hACE2-dependent S-mediated cell-cell fusion was reduced to 60 to 70% of the wild-type level for all single alanine substitutions and the Y1188A/Y1191A protein. S Δ19 proteins with other double alanine substitutions reduced cell-cell fusion further, from 40% to less than 20% of wild-type levels. The aromatic amino acids in the JMD of the SARS-CoV S glycoprotein play critical roles in receptor-dependent virus-cell and cell-cell fusion. Because the JMD is so highly conserved in all coronavirus S proteins, it is a potential target for development of drugs that may inhibit virus entry and/or cell-cell fusion mediated by S proteins of all coronaviruses.


  • SARS-CoV replicates in primary human alveolar type II cell cultures but not in type I-like cells

    by Eric C. Mossel, Jieru Wang, Scott Jeffers, Karen E. Edeen, Shuanglin Wang, Gregory P. Cosgrove, C. Joel Funk, Rizwan Manzer, Tanya A. Miura, Leonard D. Pearson, et al.


  • The Spike Glycoprotein of Murine Coronavirus MHV-JHM Mediates Receptor-Independent Infection and Spread in the Central Nervous Systems ofCeacam1a−/−Mice

    by Tanya A. Miura, Emily A. Travanty, Lauren Oko, Helle Bielefeldt-Ohmann, Susan R. Weiss, Nicole Beauchemin, Kathryn V. Holmes

    The MHV-JHM strain of the murine coronavirus mouse hepatitis virus is much more neurovirulent than the MHV-A59 strain, although both strains use murine CEACAM1a (mCEACAM1a) as the receptor to infect murine cells. We previously showed thatCeacam1a−/−mice are completely resistant to MHV-A59 infection (E. Hemmila et al., J. Virol. 78:10156-10165, 2004). In vitro, MHV-JHM, but not MHV-A59, can spread from infected murine cells to cells that lack mCEACAM1a, a phenomenon called receptor-independent spread. To determine whether MHV-JHM could infect and spread in the brain independent of mCEACAM1a, we inoculatedCeacam1a−/−mice. AlthoughCeacam1a−/−mice were completely resistant to i.c. inoculation with 106PFU of recombinant wild-type MHV-A59 (RA59) virus, these mice were killed by recombinant MHV-JHM (RJHM) and a chimeric virus containing the spike of MHV-JHM in the MHV-A59 genome (SJHM/RA59). Immunohistochemistry showed that RJHM and SJHM/RA59 infected all neural cell types and induced severe microgliosis in bothCeacam1a−/−and wild-type mice. For RJHM, the 50% lethal dose (LD50) is 1.3in wild-type mice and 103.1inCeacam1a−/−mice. For SJHM/RA59, the LD50is 1.3in wild-type mice and 103.6inCeacam1a−/−mice. This study shows that infection and spread of MHV-JHM in the brain are dependent upon the viral spike glycoprotein. RJHM can initiate infection in the brains ofCeacam1a−/−mice, but expression of mCEACAM1a increases susceptibility to infection. The spread of infection in the brain is mCEACAM1a independent. Thus, the ability of the MHV-JHM spike to mediate mCEACAM1a-independent spread in the brain is likely an important factor in the severe neurovirulence of MHV-JHM in wild-type mice.


  • Open Access

    Detection of Group 1 Coronaviruses in Bats in North America

    by Samuel R. Dominguez, Thomas J. O’sHea, Lauren M. Oko, Kathryn V. Holmes

    The epidemic of severe acute respiratory syndrome (SARS) was caused by a newly emerged coronavirus (SARS-CoV). Bats of several species in southern People’s Republic of China harbor SARS-like CoVs and may be reservoir hosts for them. To determine whether bats in North America also harbor coronaviruses, we used reverse transcription–PCR to detect coronavirus RNA in bats. We found coronavirus RNA in 6 of 28 fecal specimens from bats of 2 of 7 species tested. The prevalence of viral RNA shedding was high: 17% in Eptesicus fuscus and 50% in Myotis occultus. Sequence analysis of a 440-bp amplicon in gene 1b showed that these Rocky Mountain bat coronaviruses formed 3 clusters in phylogenetic group 1 that were distinct from group 1 coronaviruses of Asian bats. Because of the potential for bat coronaviruses to cause disease in humans and animals, further surveillance and characterization of bat coronaviruses in North America are needed.


  • Mutational Analysis of Aminopeptidase N, a Receptor for Several Group 1 Coronaviruses, Identifies Key Determinants of Viral Host Range

    by Sonia M. Tusell, Stephanie A. Schittone, Kathryn V. Holmes

    Feline coronavirus (FCoV), porcine transmissible gastroenteritis coronavirus (TGEV), canine coronavirus (CCoV), and human coronavirus HCoV-229E, which belong to the group 1 coronavirus, use aminopeptidase N (APN) of their natural host and feline APN (fAPN) as receptors. Using mouse-feline APN chimeras, we identified three small, discontinuous regions, amino acids (aa) 288 to 290, aa 732 to 746 (called R1), and aa 764 to 788 (called R2) in fAPN that determined the host ranges of these coronaviruses. Blockade of infection with anti-fAPN monoclonal antibody RG4 suggested that these three regions lie close together on the fAPN surface. Different residues in fAPN were required for infection with each coronavirus. HCoV-229E infection was blocked by an N-glycosylation sequon present between aa 288 to 290 in murine APN. TGEV required R1 of fAPN, while FCoV and CCoV required both R1 and R2 for entry. N740 and T742 in fAPN and the homologous R741 in human APN (hAPN) were key determinants of host range for FCoV, TGEV, and CCoV. Residue N740 in fAPN was essential only for CCoV receptor activity. A conservative T742V substitution or a T742R substitution in fAPN destroyed receptor activity for the pig, dog, and cat coronaviruses, while a T742S substitution retained these receptor activities. Thus, the hydroxyl on T742 is required for the coronavirus receptor activity of fAPN. In hAPN an R741T substitution caused a gain of receptor activity for TGEV but not for FCoV or CCoV. Therefore, entry and host range of these group 1 coronaviruses depend on the ability of the viral spike glycoproteins to recognize small, species-specific amino acid differences in the APN proteins of different species.


  • Open Access

    Blinded Case-Control Study of the Relationship between Human Coronavirus NL63 and Kawasaki Syndrome

    by Samuel R. Dominguez, Marsha S. Anderson, Mary P. Glodé, Christine C. Robinson, Kathryn V. Holmes

    We conducted a blinded, case-control, retrospective study in pediatric patients hospitalized at The Children’s Hospital, Denver, Colorado, to determine whether human coronavirus (HCoV)–NL63 infection is associated with Kawasaki syndrome (KS). Over the course of a 7-month period, nasopharyngeal-wash samples from 2 (7.7%) of 26 consecutive children with KS and 4 (7.7%) of 52 matched control subjects tested positive for HCoV-NL63 by reverse transcription–polymerase chain reaction. These data suggest that, although HCoV-NL63 was circulating in children in our community during the time of the study, the prevalence of infection with HCoV-NL63 was not greater in patients with KS than in control subjects.


  • RAT Coronavirus Infection of Primary RAT Alveolar Epithelial Cells

    by Kathryn V. Holmes, Robert J. Mason, Tanya A. Miura, Jieru Wang